Eculizumab Dosing Intervals Longer than 17 Days May Be Associated with Greater Risk of Breakthrough Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria

被引：44

作者：

Nakayama, Hirokazu ^{[1
]}

Usuki, Kensuke ^{[2
]}

Echizen, Hirotoshi ^{[3
]}

Ogawa, Ryuichi ^{[3
]}

Orii, Takao ^{[1
]}

机构：

[1] NTT Med Ctr Tokyo, Dept Pharm, Shinagawa Ku, 5-9-22 Higashi Gotanda, Tokyo 1418625, Japan

[2] NTT Med Ctr Tokyo, Dept Hematol, Shinagawa Ku, 5-9-22 Higashi Gotanda, Tokyo 1418625, Japan

[3] Meiji Pharmaceut Univ, Dept Pharmacotherapy, 2-522-1 Noshio, Kiyose, Tokyo 2048588, Japan

来源：

BIOLOGICAL & PHARMACEUTICAL BULLETIN | 2016年 / 39卷 / 02期

关键词：

eculizumab; dosing interval; breakthrough hemolysis; paroxysmal nocturnal hemoglobinuria; COMPLEMENT INHIBITOR ECULIZUMAB; TERM SAFETY;

D O I：

10.1248/bpb.b15-00703

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Eculizumab given bi-weekly is widely recommended for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). We undertook a retrospective analysis on the medical records of 763 dosings of 14 PNH patients to investigate whether a threshold would exist in dosing intervals associated with breakthrough hemolysis. We identified 12 events of breakthrough hemolysis in 4 patients. Multivariate logistic regression and receiver operating characteristics (ROC) analysis revealed a significant association between increased risk of breakthrough hemolysis and prolonged dosing intervals of 17 days or more and concomitant inflammation: odds ratios (OR) and 95% confidence intervals (CIs) were 1.6 (1.3-2.0, p<0.01) and 5.5 (1.3-22.8, p=0.02), respectively. ROC analysis showed that the best cut-off dosing interval discriminating breakthrough hemolysis was 16.5 days. We consider that eculizumab dosing intervals longer than 17 days may be associated with an increased risk for developing breakthrough hemolysis in patients with PNH.

引用

页码：285 / 288

页数：4

共 50 条

[41] APL-2, a complement C3 inhibitor, may potentially reduce both intravascular and extravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria
El Mehdil, Delphine
Grossi, Federico V.
Deschatelets, Pascal
Pullon, Humphrey
Tan, Lisa
Vega, Carolina A.
Francois, Cedric G.
MOLECULAR IMMUNOLOGY, 2017, 89 : 115 - 115
[42] Danicopan As Add-on Therapy to Ravulizumab or Eculizumab Versus Placebo in Patients with Paroxysmal Nocturnal Hemoglobinuria and Clinically Significant Extravascular Hemolysis: Phase 3 Long-Term Data
Kulasekararaj, Austin
Griffin, Morag
Piatek, Caroline I.
Shammo, Jamile
Nishimura, Jun-Ichi
Patriquin, Christopher J.
Schrezenmeier, Hubert
Gaya, Anna
Patel, Yogesh
Liu, Peng
Filippov, Gleb
De Fontbrune, Flore Sicre
Risitano, Antonio M.
Lee, Jong-Wook
BLOOD, 2023, 142
[43] RAVULIZUMAB VERSUS ECULIZUMAB IN ADULTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: A PROSPECTIVE ANALYSIS ON THE DEEPNESS OF C5 INHIBITION BASED ON PHARMACOKINETICS/PHARMACODYNAMICS AND BREAKTHROUGH HEMOLYSIS OBSERVED IN TWO PHASE 3 RANDOMIZED, MULTICENTER STUDIES
Risitano, A. M.
de Latour, R. Peffault
Rottinghaus, S. T.
Hillmen, P.
Ortiz, S.
Szer, J.
Schrezenmeier, H.
Aguzzi, R.
Hill, A.
Lee, J. W.
Kulasekararaj, A. G.
Brodsky, R. A.
HAEMATOLOGICA, 2019, 104 : 25 - 25
[44] Evaluation of risk for development of myeloproliferative disorders, myelodysplastic syndromes, or acute leukemias with long-term eculizumab therapy in paroxysmal nocturnal hemoglobinuria (PNH) patients
Schubert, J.
Young, N. S.
Luzzatto, L.
Brodsky, R. A.
Socie, G.
Rother, R. P.
Rollins, S. A.
Hillmen, P.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[45] Clinical Profile and Long-Term Outcomes of Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Eculizumab in a Real-World Setting: High Frequency of Anemia Despite Decreased Intravascular Hemolysis
Versmold, Katharina
Alashkar, Ferras
Raiser, Carina
Ofori-Asenso, Richard
Xu, Tao
Liu, Yutong
Katz, Pablo
Shang, Aijing
Roeth, Alexander
BLOOD, 2021, 138
[46] Post Hoc Analysis of the Effect of Pegcetacoplan Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria and Baseline Hemoglobin Levels Greater Than 10 Grams per Deciliter
Panse, Jens
Daguindau, Nicolas
Sasaki, Sonia Okuyama
De Latour, Regis Peffault
Schafhausen, Philippe
Straetmans, Nicole
Al-Adhami, Mohammed
Ajayi, Temitayo
Chen, Crystal
Yeh, Michael
Wong, Raymond S.
BLOOD, 2021, 138
[47] Prophylactic Antibiotic Use and Risk of Meningococcal Infections in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Eculizumab Who Received Meningococcal Vaccination: Results from the International PNH Registry
Patriquin, Christopher J.
Kulasekararaj, Austin
de Latour, Regis Peffault
Jang, Jun-Ho
Langemeijer, Saskia
Maschan, Alexey A.
Wilson, Amanda
Jain, Deepak
Maciejewski, Jaroslaw P.
BLOOD, 2019, 134
[48] A Phase 3 Study of Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria Naive to Complement Inhibitors: Results of a Subgroup Analysis with Patients Stratified By Baseline Hemolysis Level, Transfusion History, and Demographics
Weitz, Ilene C.
Kulagin, Aleksandr
Nakao, Shinji
Piatek, Caroline I.
Szer, Jeffrey
Rottinghaus, Scott T.
Volles, Lori
Damokosh, Andrew I.
Aguzzi, Rasha
Larratt, Loree
Risitano, Antonio M.
BLOOD, 2018, 132
[49] Use of the oral complement factor B inhibitor iptacopan in patients (pts) with paroxysmal nocturnal hemoglobinuria (PNH) with persistent hemolysis despite anti-C5 therapy: long-term efficacy and safety after stopping eculizumab (ECU)
Roth, A.
Peffault de Latour, R.
Soret, J.
Frieri, C.
Sicre de Fontbrune, F.
Marano, L.
Alashkar, F.
Benajiba, L.
Marotta, S.
Kulmatycki, K.
Nidamarthy, P. K.
Fagan, N.
Junge, G.
Risitano, A. M.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 173 - 174
[50] LDH=1. 5X ABOVE NORMAL IS A SENSITIVE AND SPECIFIC MARKER TO IDENTIFY PATIENTS AT RISK OF CLINICAL COMPLICATIONS AND MORTALITY ASSOCIATED WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
Lee, J.
Jang, J. H.
Kim, J. S.
Yoon, S. S.
Lee, J. H.
Kim, Y. K.
Jo, D. Y.
Chung, J.
Sohn, S. K.
HAEMATOLOGICA, 2012, 97 : 579 - 580

← 1 2 3 4 5 →